These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 1648791)

  • 21. [Thrombosis and thrombin].
    Hemker HC; Béguin S
    Ann Pharm Fr; 1992; 50(3):121-35. PubMed ID: 1290382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
    Greaves M;
    Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
    [No Abstract]   [Full Text] [Related]  

  • 23. Synthesis of thrombin-inhibiting heparin mimetics without side effects.
    Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
    Nature; 1999 Apr; 398(6726):417-22. PubMed ID: 10201371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
    Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A laboratory method for parallel determination of platelet aggregation and thrombin generation.
    Köstenberger M; Gallistl S; Cvirn G; Muntean W
    Clin Lab; 2004; 50(1-2):41-8. PubMed ID: 15000219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects.
    Cipriani TR; Gracher AH; de Souza LM; Fonseca RJ; Belmiro CL; Gorin PA; Sassaki GL; Iacomini M
    Thromb Haemost; 2009 May; 101(5):860-6. PubMed ID: 19404539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
    Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
    Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins.
    Messmore HL; Griffin B; Koza M; Seghatchian J; Fareed J; Coyne E
    Semin Thromb Hemost; 1991; 17 Suppl 1():57-9. PubMed ID: 1712512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin.
    Jeske WP; Hoppensteadt D; Gray A; Walenga JM; Cunanan J; Myers L; Fareed J; Bayol A; Rigal H; Viskov C
    Thromb Res; 2011 Oct; 128(4):361-7. PubMed ID: 21458847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel antithrombotic strategies in cardiovascular diseases.
    Golino P; Loffredo F; Riegler L; Renzullo E; Cocchia R
    Curr Opin Investig Drugs; 2005 Mar; 6(3):298-306. PubMed ID: 15816507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of extrinsic hemostasis activation by low-molecular-weight heparin.
    Stief TW
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):633-7. PubMed ID: 17102649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
    Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
    Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
    Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Low molecular weight heparins. Implications in anesthesia and resuscitation].
    Llau JV; Hoyas L; Ezpeleta J; García-Polit J; Barberá M; Santes MJ
    Rev Esp Anestesiol Reanim; 1997 Feb; 44(2):70-8. PubMed ID: 9148359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Heparins, antivitamins K. Principles and rules of use. Posology of non-fractionated heparins].
    Delsart D; Chambefort V; Decousus H
    Rev Prat; 2001 Sep; 51(13):1489-97. PubMed ID: 11601082
    [No Abstract]   [Full Text] [Related]  

  • 37. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
    Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N
    Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental and clinical pharmacology of pentosan polysulfate.
    Maffrand JP; Herbert JM; Bernat A; Defreyn G; Delebassee D; Savi P; Pinot JJ; Sampol J
    Semin Thromb Hemost; 1991; 17 Suppl 2():186-98. PubMed ID: 1719639
    [No Abstract]   [Full Text] [Related]  

  • 39. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ex vivo correlate of the antithrombotic action of heparin.
    Hemker HC; Béguin S; Pieters J; Lindhout T
    Ann N Y Acad Sci; 1989; 556():146-57. PubMed ID: 2544125
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.